TABLE 2.

Current Radiopharmaceutical Trials in PCa

Trial nameClinicalTrials.gov numberPhaseSize (n)RegimenGeographic region
High-risk localized or oligometastatic PCa
 LutectomyNCT04430192II20177Lu-PSMA-617 before prostatectomyAustralia
 BullseyeNCT04443062II58177Lu-PSMA-617 vs. standard of careThe Netherlands
 PROQURE-1NCT05162573I18EBRT + 177Lu-PSMA-617The Netherlands
Metastatic CRPC
 UpFrontPSMANCT04343885II140Docetaxel ± 177Lu-PSMA-617Australia
 ProstACT TARGETNCT05146973II50EBRT + 177Lu-DOTA-TLX591Australia
 PSMAdditionNCT04720157III1,126Standard of care ± 177Lu-PSMA-617United States, Europe, Korea, Singapore, Taiwan
 NANCT04206319II26223RaUnited States
 NANCT05079698I6177Lu-PSMA-617 + stereotactic radiotherapyUnited States
First-line therapy for metastatic CRPC
 EnzaPNCT04419402II160Enzalutamide ± 177Lu-PSMA-617Australia
 PSMAforeNCT04689828III450177Lu-PSMA-617 vs. change in ARSINorth America, Europe
Second-line therapy for metastatic CRPC
 LuPARPNCT03874884I52177Lu-PSMA-617 + olaparibAustralia
 PRINCENCT03658447I/II37177Lu-PSMA-617 + pembrolizumabAustralia
 NANCT03805594I43177Lu-PSMA-617 + pembrolizumabUnited States
 NANCT04946370I/II76225Ac-J591 + pembrolizumabUnited States
 SPLASHNCT04647526III415177Lu-PSMA-I&T vs. second-line ARSINorth America, Europe
 NANCT04506567I/II105225Ac-J591United States
 ARROWNCT03939689II120Enzalutamide ± MIP 1095 131INorth America
 NANCT04644770I70225Ac h11B6United States
 SECuRENCT04868604I/II4464Cu-SAR-bisPSMAUnited States
 LuCABNCT05340374I/II44177Lu-PSMA-617 + cabazitaxelAustralia
 NANCT04071236I/II24223Ra ± M3814 ± avelumabUnited States
 TATCISTNCT05219500II100225Ac-PSMA-I&TUnited States
 NANCT04886986I/II33225Ac + 177Lu-PSMA-I&TUnited States
 ECLIPSENCT05204927III400177Lu-PSMA-I&TUnited States
 NANCT04597411I30225Ac-PSMA-617Australia, South Africa
 PROSTACTNCT04876651III387177Lu-J591Australia

  • EBRT = external beam radiotherapy; ARSI = androgen receptor signaling inhibitor; NA = not applicable.